Equity Incentive Plans (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

A summary of the status of the Company’s option plans as of March 31, 2018 and changes during the period then ended is presented below:

	Three months ended March 31, 2018
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		14,806,027		$	10.64
Granted		1,904,634			21.15
Exercised		(500,166	)		5.27
Forfeited and cancelled		(71,307	)		11.86
Outstanding as of March 31, 2018		16,139,188		$	12.04

Exercisable options		7,375,692		$	9.31

Schedule of RSU's

A summary of the status of the Company’s RSUs as of March 31, 2018 and changes during the period then ended is presented below:

	Three months ended March 31, 2018
	Unaudited
	Number of RSUs			Weighted average grant date fair value price
Unvested at beginning of year		1,651,219		$	9.66
Granted		427,518			21.15
Vested		(256,578	)		7.15
Forfeited and cancelled		(7,669	)		8.49
Unvested as of March 31, 2018		1,814,490		$	12.73

Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model

The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model, with the following underlying assumptions:

	Three months ended March 31,						Year ended December 31,
	2018			2017			2017
	Unaudited						Audited
Stock Option Plans
Expected term (years)	6.25			6.25			5.5-6.25
Expected volatility		55.04	%		59.15	%	56.74%-59.45%
Risk-free interest rate		2.77	%		2.23	%	1.97%-2.23%
Dividend yield	0.00%			0.00%			0.00%
ESPP
Expected term (years)	0.50			0.50			0.50
Expected volatility		52.58	%	82.00%			76.37%-82.00%
Risk-free interest rate		1.61	%	0.62%			0.62%-1.13%
Dividend yield	0.00%			0.00%			0.00%

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three months ended March 31, 2018 and 2017 and the year ended December 31, 2017 was:

	Three months ended March 31,				Year ended December 31,
	2018		2017		2017
	Unaudited				Audited
Cost of revenues	$	164	$	143	$	467
Research, development and clinical trials		906		862		3,587
Sales and marketing		1,436		655		3,784
General and administrative		6,014		2,901		19,278
Total share-based compensation expense	$	8,520	$	4,561	$	27,116